Draft:Tarek Fahmy
Biomedical engineer and academic
From Wikipedia, the free encyclopedia
Tarek Fahmy is a biomedical engineer and academic at Yale University. He is an associate professor of biomedical engineering and immunobiology whose research focuses on biomaterials, drug delivery, and immunoengineering.[1][2] He is known for work on biodegradable artificial antigen-presenting cells and nanogel-based delivery systems for cancer immunotherapy and autoimmune disease treatment.[3][4][5]
 | Review waiting, please be patient.
This may take 2 months or more, since drafts are reviewed in no specific order. There are 4,352 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Education and career
Fahmy received a B.Sc. from the University of Delaware, followed by an M.S. and Ph.D. from Johns Hopkins University.[6] He later joined the Yale faculty and holds appointments in Biomedical Engineering and Immunobiology.[1][2]
Research
Fahmy's research focuses on the design of biomaterials for drug and antigen delivery to the immune system.[1][7] In 2008, he and Erin R. Steenblock reported a biodegradable polymeric artificial antigen-presenting cell platform for ex vivo T-cell expansion.[3]
Subsequent work from his laboratory examined the use of carbon nanotube bundles to enhance T-cell activation for adoptive immunotherapy.[8] In 2012, Fahmy and collaborators reported a nanolipogel platform that co-delivered interleukin-2 and a TGF-β inhibitor to tumors, a system later described in a Nature Materials News & Views article as engaging both innate and adaptive immune responses in tumour immunotherapy.[9][4][10]
In 2013, Fahmy co-authored a study on nanogel-based delivery of mycophenolic acid in lupus-prone mice, which was highlighted by the Journal of Clinical Investigation and by Yale News as a potential targeted therapy for autoimmune disease.[5][11][12] In 2016, Yale announced that a nanogel-based immunotherapy platform developed in his laboratory was moving toward a first phase of clinical trials for metastatic cancer.[13]
Honors
Fahmy received a Wallace H. Coulter Foundation Early Career Award in 2006.[1] He later received an NSF CAREER Award for research on biomaterials designed to manipulate immune responses against cancer and other diseases.[7]
Selected publications
- A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells (2008)[3]
- Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy (2012)[9]
- Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice (2013)[5]